Summit Therapeutics (SMMT) Stock: Buy, Sell, or Hold?
SMMT - Summit Therapeutics Inc. Common Stock
$16.76
0.06 (0.39%)
â˛
5d:
+7.34%
30d:
+14.76%
90d:
+5.18%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 19, 2026
15d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 29, 2026 at $16.39 · last confirmed Oct 2, 2026
Strength: 6.4/10
Get Alerted When SMMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SMMT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SMMT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SMMT is currently trading at $16.75, which is considered fair relative to its 30-day fair value range of $14.58 to $17.71.
Technical Outlook: Technically, SMMT is in a strong uptrend. Immediate support is located at $15.18, while resistance sits at $19.09.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $29.69 (+77.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SMMT is in a strong uptrend. Immediate support is located at $15.18, while resistance sits at $19.09.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $29.69 (+77.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$14.58 -
$17.71
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 77.2% below Wall St target ($29.69)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.58 -
$17.71
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$15.18
Resistance Level
$19.09
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.44
Wall Street Target
$29.69
(+77.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 02, 2026 8:21 PM ET
Data refreshes hourly during market hours. Next update: 9:21 PM
Data refreshes hourly during market hours. Next update: 9:21 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
